Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAA) is a blank-check special purpose acquisition company that completed its initial public offering in January 2025, with its final 424B4 prospectus filed with the SEC on January 29, 2025. The vehicle is focused on the domestic pharmaceutical and drug manufacturing sector, targeting merger or acquisition candidates within the life sciences and specialty pharmaceutical space at a time of heightened policy interest in onshoring U.S. drug production. DMAA is currently in its search phase, pursuing a qualifying business combination. To access complete filing data, deal timelines, and sponsor profiles for DMAA and hundreds of other active SPACs, sign up for full data on SpacDesk.